AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 15, 2017, the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) appointed Suzanne Bruhn as a Class I director, effective as of the same date.
Ms. Bruhn will receive an annual cash retainer of $35,000 per year in accordance with the Company’s existing compensation policy for non-employee directors. In addition, the Board granted to Ms. Bruhn, effective February 15, 2017, a stock option to purchase 82,000 shares of common stock at an exercise price of $5.04 per share, which will vest monthly over three years, subject to Ms. Bruhn’s continued service to the Company.
The Company has entered into its standard form of indemnification agreement with Ms. Bruhn. A form of the indemnification agreement was previously filed by the Company as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on September 14, 2015.
There is no arrangement or understanding with any person to which Ms. Bruhn was appointed as a member of the Board, and Ms. Bruhn does not have any direct or indirect material interest in any transaction required to be disclosed to Item 404(a) of Regulation S-K.
About AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE)
Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria. AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) Recent Trading Information
AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) closed its last trading session up +0.06 at 5.10 with 115,908 shares trading hands.
An ad to help with our costs